Effects of verteporfin therapy on contrast sensitivity: Results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation - TAP Report No. 4

Gary S. Rubin; Neil M. Bressler; Jennifer Arnold; Dara Kilmartin; John Olson; Sean Neville; Karon Robinson; Allison Laird; Claire Richmond; Alison Farrow; Sandra McKay; Rhona McKechnie; Gary Evans; Andrew P. Schachat; Neil M. Bressler; Susan B. Bressler; Pat Nesbitt; Tracey Porter; Patricia Hawse; Mike Hartnett; Ann Eager; Judy Belt; Dennis Cain; David Emmert; Terry George; Mark Herring; Jaquelyn McDonald; Jordi Monés; Borja Corcóstegui; Montse Gilbert; Nuria Duran; Maite Sisquella; Ana Nolla; Alfons Margalef; Joan W. Miller; Evangelos S. Gragoudas; Anne Marie Lane; Nicholas Emmanuel; Amy Holbrook; Claudia Evans; Ursula Szajta Lord; Davis K. Walsh; Charlene D. Callahan; Jennifer L. DuBois; Jennifer Moy; Alice George Kenney; Inge Milde; Eric S. Platz; Hilel Lewis; Peter K. Kaiser; Laura J. Holody; Erica Lesak; Susan Lichterman; Helene Siegel; Anthony Fattori; Ginny Ambrose; Tami Fecko; Deborah Ross; Stephanie Burke; Joyce Conway; Lawrence Singerman; Hernando Zegarra; Michael Novak; Michelle Bartel; Kimberly Tilocco-DuBois; Mary Ilc; Stephanie Schura; Sheri Joyce; Vivian Tanner; Pam Rowe; Sheila Smith-Brewer; Donna Kukula; Greg Greanoff; Geraldine Daley; John DuBois; David Lehnhardt; Gary Edd Fish; Bradley F. Jost; Rajiv Anand; David Callanan; Sally Arceneaux; Jean Arnwine; Penny Ellenich; John King; Hank Aguado; Rubye Collins; Teresa Anderson; Cynthia Nork; Karen Duignan; Bob Boleman; Constantin J. Poumaras; Guy Donati; Anastasios D. Kapetanios; Katty Cavalière; S. Guney-Wagner; N. Gerber; Michel Sickenberg; Valérie Sickenberg; Alice Gans

doi:10.1097/00006982-200210000-00002

Effects of verteporfin therapy on contrast sensitivity: Results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation - TAP Report No. 4

Gary S. Rubin, Neil M. Bressler, Jennifer Arnold, Dara Kilmartin, John Olson, Sean Neville, Karon Robinson, Allison Laird, Claire Richmond, Alison Farrow, Sandra McKay, Rhona McKechnie, Gary Evans, Andrew P. Schachat, Neil M. Bressler, Susan B. Bressler, Pat Nesbitt, Tracey Porter, Patricia Hawse, Mike HartnettAnn Eager, Judy Belt, Dennis Cain, David Emmert, Terry George, Mark Herring, Jaquelyn McDonald, Jordi Monés, Borja Corcóstegui, Montse Gilbert, Nuria Duran, Maite Sisquella, Ana Nolla, Alfons Margalef, Joan W. Miller, Evangelos S. Gragoudas, Anne Marie Lane, Nicholas Emmanuel, Amy Holbrook, Claudia Evans, Ursula Szajta Lord, Davis K. Walsh, Charlene D. Callahan, Jennifer L. DuBois, Jennifer Moy, Alice George Kenney, Inge Milde, Eric S. Platz, Hilel Lewis, Peter K. Kaiser, Laura J. Holody, Erica Lesak, Susan Lichterman, Helene Siegel, Anthony Fattori, Ginny Ambrose, Tami Fecko, Deborah Ross, Stephanie Burke, Joyce Conway, Lawrence Singerman, Hernando Zegarra, Michael Novak, Michelle Bartel, Kimberly Tilocco-DuBois, Mary Ilc, Stephanie Schura, Sheri Joyce, Vivian Tanner, Pam Rowe, Sheila Smith-Brewer, Donna Kukula, Greg Greanoff, Geraldine Daley, John DuBois, David Lehnhardt, Gary Edd Fish, Bradley F. Jost, Rajiv Anand, David Callanan, Sally Arceneaux, Jean Arnwine, Penny Ellenich, John King, Hank Aguado, Rubye Collins, Teresa Anderson, Cynthia Nork, Karen Duignan, Bob Boleman, Constantin J. Poumaras, Guy Donati, Anastasios D. Kapetanios, Katty Cavalière, S. Guney-Wagner, N. Gerber, Michel Sickenberg, Valérie Sickenberg, Alice Gans

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Abstract

Background: In the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation, verteporfin therapy reduced the risk of at least moderate vision loss (defined as a loss of at least 15 letters of visual acuity) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). This report presents detailed analyses of 24-month contrast sensitivity outcomes in these patients. Methods: The patients included in the TAP investigation had subfoveal CNV secondary to ARMD and received verteporfin therapy (n = 402) or placebo (n = 207) at the first visit, with retreatment at each 3-month follow-up visit if angiography revealed fluorescein leakage from CNV. Contrast sensitivity was determined at each visit using a Pelli-Robson chart. Results: At the month 24 examination, verteporfin-treated patients were less likely to lose at least 6 or 15 letters of contrast sensitivity than placebo-treated patients (86 [21%] versus 94 [45%], and 27 [7%] versus 24 [12%], respectively; P < 0.05 for both comparisons). The superiority of verteporfin therapy over placebo was greater in patients with predominantly classic CNV at baseline, although verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes. Conclusions: Consistent with visual acuity outcomes, verteporfin therapy reduced the risk of a clinically relevant loss of contrast sensitivity in the total study population, with the greatest effect in patients with predominantly classic subfoveal CNV secondary to ARMD. Verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes than patients who received placebo. Given the association between contrast sensitivity and visual disability, the beneficial effects of verteporfin therapy on contrast sensitivity outcomes are expected to have a favorable impact on patients' daily activities.

Original language	English (US)
Pages (from-to)	536-544
Number of pages	9
Journal	Retina
Volume	22
Issue number	5
DOIs	https://doi.org/10.1097/00006982-200210000-00002
State	Published - Oct 2002
Externally published	Yes

Keywords

Age-related macular degeneration
Choroidal neovascularization
Contrast sensitivity
Verteporfin
Visual function

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1097/00006982-200210000-00002

Cite this

Rubin, G. S., Bressler, N. M., Arnold, J., Kilmartin, D., Olson, J., Neville, S., Robinson, K., Laird, A., Richmond, C., Farrow, A., McKay, S., McKechnie, R., Evans, G., Schachat, A. P., Bressler, N. M., Bressler, S. B., Nesbitt, P., Porter, T., Hawse, P., ... Gans, A. (2002). Effects of verteporfin therapy on contrast sensitivity: Results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation - TAP Report No. 4. Retina, 22(5), 536-544. https://doi.org/10.1097/00006982-200210000-00002

Rubin, GS, Bressler, NM, Arnold, J, Kilmartin, D, Olson, J, Neville, S, Robinson, K, Laird, A, Richmond, C, Farrow, A, McKay, S, McKechnie, R, Evans, G, Schachat, AP, Bressler, NM, Bressler, SB, Nesbitt, P, Porter, T, Hawse, P, Hartnett, M, Eager, A, Belt, J, Cain, D, Emmert, D, George, T, Herring, M, McDonald, J, Monés, J, Corcóstegui, B, Gilbert, M, Duran, N, Sisquella, M, Nolla, A, Margalef, A, Miller, JW, Gragoudas, ES, Lane, AM, Emmanuel, N, Holbrook, A, Evans, C, Lord, US, Walsh, DK, Callahan, CD, DuBois, JL, Moy, J, Kenney, AG, Milde, I, Platz, ES, Lewis, H, Kaiser, PK, Holody, LJ, Lesak, E, Lichterman, S, Siegel, H, Fattori, A, Ambrose, G, Fecko, T, Ross, D, Burke, S, Conway, J, Singerman, L, Zegarra, H, Novak, M, Bartel, M, Tilocco-DuBois, K, Ilc, M, Schura, S, Joyce, S, Tanner, V, Rowe, P, Smith-Brewer, S, Kukula, D, Greanoff, G, Daley, G, DuBois, J, Lehnhardt, D, Fish, GE, Jost, BF, Anand, R, Callanan, D, Arceneaux, S, Arnwine, J, Ellenich, P, King, J, Aguado, H, Collins, R, Anderson, T, Nork, C, Duignan, K, Boleman, B, Poumaras, CJ, Donati, G, Kapetanios, AD, Cavalière, K, Guney-Wagner, S, Gerber, N, Sickenberg, M, Sickenberg, V & Gans, A 2002, 'Effects of verteporfin therapy on contrast sensitivity: Results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation - TAP Report No. 4', Retina, vol. 22, no. 5, pp. 536-544. https://doi.org/10.1097/00006982-200210000-00002

@article{06cf6b6996ba476db64f98d1011a085a,

title = "Effects of verteporfin therapy on contrast sensitivity: Results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation - TAP Report No. 4",

abstract = "Background: In the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation, verteporfin therapy reduced the risk of at least moderate vision loss (defined as a loss of at least 15 letters of visual acuity) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). This report presents detailed analyses of 24-month contrast sensitivity outcomes in these patients. Methods: The patients included in the TAP investigation had subfoveal CNV secondary to ARMD and received verteporfin therapy (n = 402) or placebo (n = 207) at the first visit, with retreatment at each 3-month follow-up visit if angiography revealed fluorescein leakage from CNV. Contrast sensitivity was determined at each visit using a Pelli-Robson chart. Results: At the month 24 examination, verteporfin-treated patients were less likely to lose at least 6 or 15 letters of contrast sensitivity than placebo-treated patients (86 [21%] versus 94 [45%], and 27 [7%] versus 24 [12%], respectively; P < 0.05 for both comparisons). The superiority of verteporfin therapy over placebo was greater in patients with predominantly classic CNV at baseline, although verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes. Conclusions: Consistent with visual acuity outcomes, verteporfin therapy reduced the risk of a clinically relevant loss of contrast sensitivity in the total study population, with the greatest effect in patients with predominantly classic subfoveal CNV secondary to ARMD. Verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes than patients who received placebo. Given the association between contrast sensitivity and visual disability, the beneficial effects of verteporfin therapy on contrast sensitivity outcomes are expected to have a favorable impact on patients' daily activities.",

keywords = "Age-related macular degeneration, Choroidal neovascularization, Contrast sensitivity, Verteporfin, Visual function",

author = "Rubin, {Gary S.} and Bressler, {Neil M.} and Jennifer Arnold and Dara Kilmartin and John Olson and Sean Neville and Karon Robinson and Allison Laird and Claire Richmond and Alison Farrow and Sandra McKay and Rhona McKechnie and Gary Evans and Schachat, {Andrew P.} and Bressler, {Neil M.} and Bressler, {Susan B.} and Pat Nesbitt and Tracey Porter and Patricia Hawse and Mike Hartnett and Ann Eager and Judy Belt and Dennis Cain and David Emmert and Terry George and Mark Herring and Jaquelyn McDonald and Jordi Mon{\'e}s and Borja Corc{\'o}stegui and Montse Gilbert and Nuria Duran and Maite Sisquella and Ana Nolla and Alfons Margalef and Miller, {Joan W.} and Gragoudas, {Evangelos S.} and Lane, {Anne Marie} and Nicholas Emmanuel and Amy Holbrook and Claudia Evans and Lord, {Ursula Szajta} and Walsh, {Davis K.} and Callahan, {Charlene D.} and DuBois, {Jennifer L.} and Jennifer Moy and Kenney, {Alice George} and Inge Milde and Platz, {Eric S.} and Hilel Lewis and Kaiser, {Peter K.} and Holody, {Laura J.} and Erica Lesak and Susan Lichterman and Helene Siegel and Anthony Fattori and Ginny Ambrose and Tami Fecko and Deborah Ross and Stephanie Burke and Joyce Conway and Lawrence Singerman and Hernando Zegarra and Michael Novak and Michelle Bartel and Kimberly Tilocco-DuBois and Mary Ilc and Stephanie Schura and Sheri Joyce and Vivian Tanner and Pam Rowe and Sheila Smith-Brewer and Donna Kukula and Greg Greanoff and Geraldine Daley and John DuBois and David Lehnhardt and Fish, {Gary Edd} and Jost, {Bradley F.} and Rajiv Anand and David Callanan and Sally Arceneaux and Jean Arnwine and Penny Ellenich and John King and Hank Aguado and Rubye Collins and Teresa Anderson and Cynthia Nork and Karen Duignan and Bob Boleman and Poumaras, {Constantin J.} and Guy Donati and Kapetanios, {Anastasios D.} and Katty Cavali{\`e}re and S. Guney-Wagner and N. Gerber and Michel Sickenberg and Val{\'e}rie Sickenberg and Alice Gans",

year = "2002",

month = oct,

doi = "10.1097/00006982-200210000-00002",

language = "English (US)",

volume = "22",

pages = "536--544",

journal = "Retina",

issn = "0275-004X",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Effects of verteporfin therapy on contrast sensitivity

T2 - Results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation - TAP Report No. 4

AU - Rubin, Gary S.

AU - Bressler, Neil M.

AU - Arnold, Jennifer

AU - Kilmartin, Dara

AU - Olson, John

AU - Neville, Sean

AU - Robinson, Karon

AU - Laird, Allison

AU - Richmond, Claire

AU - Farrow, Alison

AU - McKay, Sandra

AU - McKechnie, Rhona

AU - Evans, Gary

AU - Schachat, Andrew P.

AU - Bressler, Neil M.

AU - Bressler, Susan B.

AU - Nesbitt, Pat

AU - Porter, Tracey

AU - Hawse, Patricia

AU - Hartnett, Mike

AU - Eager, Ann

AU - Belt, Judy

AU - Cain, Dennis

AU - Emmert, David

AU - George, Terry

AU - Herring, Mark

AU - McDonald, Jaquelyn

AU - Monés, Jordi

AU - Corcóstegui, Borja

AU - Gilbert, Montse

AU - Duran, Nuria

AU - Sisquella, Maite

AU - Nolla, Ana

AU - Margalef, Alfons

AU - Miller, Joan W.

AU - Gragoudas, Evangelos S.

AU - Lane, Anne Marie

AU - Emmanuel, Nicholas

AU - Holbrook, Amy

AU - Evans, Claudia

AU - Lord, Ursula Szajta

AU - Walsh, Davis K.

AU - Callahan, Charlene D.

AU - DuBois, Jennifer L.

AU - Moy, Jennifer

AU - Kenney, Alice George

AU - Milde, Inge

AU - Platz, Eric S.

AU - Lewis, Hilel

AU - Kaiser, Peter K.

AU - Holody, Laura J.

AU - Lesak, Erica

AU - Lichterman, Susan

AU - Siegel, Helene

AU - Fattori, Anthony

AU - Ambrose, Ginny

AU - Fecko, Tami

AU - Ross, Deborah

AU - Burke, Stephanie

AU - Conway, Joyce

AU - Singerman, Lawrence

AU - Zegarra, Hernando

AU - Novak, Michael

AU - Bartel, Michelle

AU - Tilocco-DuBois, Kimberly

AU - Ilc, Mary

AU - Schura, Stephanie

AU - Joyce, Sheri

AU - Tanner, Vivian

AU - Rowe, Pam

AU - Smith-Brewer, Sheila

AU - Kukula, Donna

AU - Greanoff, Greg

AU - Daley, Geraldine

AU - DuBois, John

AU - Lehnhardt, David

AU - Fish, Gary Edd

AU - Jost, Bradley F.

AU - Anand, Rajiv

AU - Callanan, David

AU - Arceneaux, Sally

AU - Arnwine, Jean

AU - Ellenich, Penny

AU - King, John

AU - Aguado, Hank

AU - Collins, Rubye

AU - Anderson, Teresa

AU - Nork, Cynthia

AU - Duignan, Karen

AU - Boleman, Bob

AU - Poumaras, Constantin J.

AU - Donati, Guy

AU - Kapetanios, Anastasios D.

AU - Cavalière, Katty

AU - Guney-Wagner, S.

AU - Gerber, N.

AU - Sickenberg, Michel

AU - Sickenberg, Valérie

AU - Gans, Alice

PY - 2002/10

Y1 - 2002/10

N2 - Background: In the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation, verteporfin therapy reduced the risk of at least moderate vision loss (defined as a loss of at least 15 letters of visual acuity) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). This report presents detailed analyses of 24-month contrast sensitivity outcomes in these patients. Methods: The patients included in the TAP investigation had subfoveal CNV secondary to ARMD and received verteporfin therapy (n = 402) or placebo (n = 207) at the first visit, with retreatment at each 3-month follow-up visit if angiography revealed fluorescein leakage from CNV. Contrast sensitivity was determined at each visit using a Pelli-Robson chart. Results: At the month 24 examination, verteporfin-treated patients were less likely to lose at least 6 or 15 letters of contrast sensitivity than placebo-treated patients (86 [21%] versus 94 [45%], and 27 [7%] versus 24 [12%], respectively; P < 0.05 for both comparisons). The superiority of verteporfin therapy over placebo was greater in patients with predominantly classic CNV at baseline, although verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes. Conclusions: Consistent with visual acuity outcomes, verteporfin therapy reduced the risk of a clinically relevant loss of contrast sensitivity in the total study population, with the greatest effect in patients with predominantly classic subfoveal CNV secondary to ARMD. Verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes than patients who received placebo. Given the association between contrast sensitivity and visual disability, the beneficial effects of verteporfin therapy on contrast sensitivity outcomes are expected to have a favorable impact on patients' daily activities.

AB - Background: In the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation, verteporfin therapy reduced the risk of at least moderate vision loss (defined as a loss of at least 15 letters of visual acuity) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). This report presents detailed analyses of 24-month contrast sensitivity outcomes in these patients. Methods: The patients included in the TAP investigation had subfoveal CNV secondary to ARMD and received verteporfin therapy (n = 402) or placebo (n = 207) at the first visit, with retreatment at each 3-month follow-up visit if angiography revealed fluorescein leakage from CNV. Contrast sensitivity was determined at each visit using a Pelli-Robson chart. Results: At the month 24 examination, verteporfin-treated patients were less likely to lose at least 6 or 15 letters of contrast sensitivity than placebo-treated patients (86 [21%] versus 94 [45%], and 27 [7%] versus 24 [12%], respectively; P < 0.05 for both comparisons). The superiority of verteporfin therapy over placebo was greater in patients with predominantly classic CNV at baseline, although verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes. Conclusions: Consistent with visual acuity outcomes, verteporfin therapy reduced the risk of a clinically relevant loss of contrast sensitivity in the total study population, with the greatest effect in patients with predominantly classic subfoveal CNV secondary to ARMD. Verteporfin-treated patients with minimally classic CNV also had better contrast sensitivity outcomes than patients who received placebo. Given the association between contrast sensitivity and visual disability, the beneficial effects of verteporfin therapy on contrast sensitivity outcomes are expected to have a favorable impact on patients' daily activities.

KW - Age-related macular degeneration

KW - Choroidal neovascularization

KW - Contrast sensitivity

KW - Verteporfin

KW - Visual function

UR - http://www.scopus.com/inward/record.url?scp=0036796124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036796124&partnerID=8YFLogxK

U2 - 10.1097/00006982-200210000-00002

DO - 10.1097/00006982-200210000-00002

M3 - Article

C2 - 12441717

AN - SCOPUS:0036796124

SN - 0275-004X

VL - 22

SP - 536

EP - 544

JO - Retina

JF - Retina

IS - 5

ER -

Effects of verteporfin therapy on contrast sensitivity: Results from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation - TAP Report No. 4

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this